Fasting potentiates the anticancer activity of tyrosine kinase inhibitors by strengthening MAPK signaling inhibition

Irene Caffa, Vito D'Agostino, Patrizia Damonte, Debora Soncini, Michele Cea, Fiammetta Monacelli, Patrizio Odetti, Alberto Ballestrero, Alessandro Provenzani, Valter D. Longo, Alessio Nencioni

Research output: Contribution to journalArticle

Abstract

Tyrosine kinase inhibitors (TKIs) are now the mainstay of treatment in many types of cancer. However, their benefit is frequently short-lived, mandating the search for safe potentiation strategies. Cycles of fasting enhance the activity of chemo-radiotherapy in preclinical cancer models and dietary approaches based on fasting are currently explored in clinical trials. Whether combining fasting with TKIs is going to be potentially beneficial remains unknown. Here we report that starvation conditions increase the ability of commonly administered TKIs, including erlotinib, gefitinib, lapatinib, crizotinib and regorafenib, to block cancer cell growth, to inhibit the mitogen-activated protein kinase (MAPK) signaling pathway and to strengthen E2F-dependent transcription inhibition. In cancer xenografts models, both TKIs and cycles of fasting slowed tumor growth, but, when combined, these interventions were significantly more effective than either type of treatment alone. In conclusion, cycles of fasting or of specifically designed fasting-mimicking diets should be evaluated in clinical studies as a means to potentiate the activity of TKIs in clinical use.

Original languageEnglish
Pages (from-to)11820-11832
Number of pages13
JournalOncotarget
Volume6
Issue number14
Publication statusPublished - 2015

Fingerprint

Mitogen-Activated Protein Kinases
Protein-Tyrosine Kinases
Fasting
Neoplasms
Aptitude
Growth
Starvation
Heterografts
Inhibition (Psychology)
Radiotherapy
Clinical Trials
Diet
Therapeutics

Keywords

  • Cell cycle regulation
  • E2F transcription factors
  • Fasting
  • MAPK pathway
  • Tyrosine kinase inhibitors

ASJC Scopus subject areas

  • Oncology

Cite this

Caffa, I., D'Agostino, V., Damonte, P., Soncini, D., Cea, M., Monacelli, F., ... Nencioni, A. (2015). Fasting potentiates the anticancer activity of tyrosine kinase inhibitors by strengthening MAPK signaling inhibition. Oncotarget, 6(14), 11820-11832.

Fasting potentiates the anticancer activity of tyrosine kinase inhibitors by strengthening MAPK signaling inhibition. / Caffa, Irene; D'Agostino, Vito; Damonte, Patrizia; Soncini, Debora; Cea, Michele; Monacelli, Fiammetta; Odetti, Patrizio; Ballestrero, Alberto; Provenzani, Alessandro; Longo, Valter D.; Nencioni, Alessio.

In: Oncotarget, Vol. 6, No. 14, 2015, p. 11820-11832.

Research output: Contribution to journalArticle

Caffa, I, D'Agostino, V, Damonte, P, Soncini, D, Cea, M, Monacelli, F, Odetti, P, Ballestrero, A, Provenzani, A, Longo, VD & Nencioni, A 2015, 'Fasting potentiates the anticancer activity of tyrosine kinase inhibitors by strengthening MAPK signaling inhibition', Oncotarget, vol. 6, no. 14, pp. 11820-11832.
Caffa I, D'Agostino V, Damonte P, Soncini D, Cea M, Monacelli F et al. Fasting potentiates the anticancer activity of tyrosine kinase inhibitors by strengthening MAPK signaling inhibition. Oncotarget. 2015;6(14):11820-11832.
Caffa, Irene ; D'Agostino, Vito ; Damonte, Patrizia ; Soncini, Debora ; Cea, Michele ; Monacelli, Fiammetta ; Odetti, Patrizio ; Ballestrero, Alberto ; Provenzani, Alessandro ; Longo, Valter D. ; Nencioni, Alessio. / Fasting potentiates the anticancer activity of tyrosine kinase inhibitors by strengthening MAPK signaling inhibition. In: Oncotarget. 2015 ; Vol. 6, No. 14. pp. 11820-11832.
@article{14172585f7e84bf7bda5321cd8ed8071,
title = "Fasting potentiates the anticancer activity of tyrosine kinase inhibitors by strengthening MAPK signaling inhibition",
abstract = "Tyrosine kinase inhibitors (TKIs) are now the mainstay of treatment in many types of cancer. However, their benefit is frequently short-lived, mandating the search for safe potentiation strategies. Cycles of fasting enhance the activity of chemo-radiotherapy in preclinical cancer models and dietary approaches based on fasting are currently explored in clinical trials. Whether combining fasting with TKIs is going to be potentially beneficial remains unknown. Here we report that starvation conditions increase the ability of commonly administered TKIs, including erlotinib, gefitinib, lapatinib, crizotinib and regorafenib, to block cancer cell growth, to inhibit the mitogen-activated protein kinase (MAPK) signaling pathway and to strengthen E2F-dependent transcription inhibition. In cancer xenografts models, both TKIs and cycles of fasting slowed tumor growth, but, when combined, these interventions were significantly more effective than either type of treatment alone. In conclusion, cycles of fasting or of specifically designed fasting-mimicking diets should be evaluated in clinical studies as a means to potentiate the activity of TKIs in clinical use.",
keywords = "Cell cycle regulation, E2F transcription factors, Fasting, MAPK pathway, Tyrosine kinase inhibitors",
author = "Irene Caffa and Vito D'Agostino and Patrizia Damonte and Debora Soncini and Michele Cea and Fiammetta Monacelli and Patrizio Odetti and Alberto Ballestrero and Alessandro Provenzani and Longo, {Valter D.} and Alessio Nencioni",
year = "2015",
language = "English",
volume = "6",
pages = "11820--11832",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals LLC",
number = "14",

}

TY - JOUR

T1 - Fasting potentiates the anticancer activity of tyrosine kinase inhibitors by strengthening MAPK signaling inhibition

AU - Caffa, Irene

AU - D'Agostino, Vito

AU - Damonte, Patrizia

AU - Soncini, Debora

AU - Cea, Michele

AU - Monacelli, Fiammetta

AU - Odetti, Patrizio

AU - Ballestrero, Alberto

AU - Provenzani, Alessandro

AU - Longo, Valter D.

AU - Nencioni, Alessio

PY - 2015

Y1 - 2015

N2 - Tyrosine kinase inhibitors (TKIs) are now the mainstay of treatment in many types of cancer. However, their benefit is frequently short-lived, mandating the search for safe potentiation strategies. Cycles of fasting enhance the activity of chemo-radiotherapy in preclinical cancer models and dietary approaches based on fasting are currently explored in clinical trials. Whether combining fasting with TKIs is going to be potentially beneficial remains unknown. Here we report that starvation conditions increase the ability of commonly administered TKIs, including erlotinib, gefitinib, lapatinib, crizotinib and regorafenib, to block cancer cell growth, to inhibit the mitogen-activated protein kinase (MAPK) signaling pathway and to strengthen E2F-dependent transcription inhibition. In cancer xenografts models, both TKIs and cycles of fasting slowed tumor growth, but, when combined, these interventions were significantly more effective than either type of treatment alone. In conclusion, cycles of fasting or of specifically designed fasting-mimicking diets should be evaluated in clinical studies as a means to potentiate the activity of TKIs in clinical use.

AB - Tyrosine kinase inhibitors (TKIs) are now the mainstay of treatment in many types of cancer. However, their benefit is frequently short-lived, mandating the search for safe potentiation strategies. Cycles of fasting enhance the activity of chemo-radiotherapy in preclinical cancer models and dietary approaches based on fasting are currently explored in clinical trials. Whether combining fasting with TKIs is going to be potentially beneficial remains unknown. Here we report that starvation conditions increase the ability of commonly administered TKIs, including erlotinib, gefitinib, lapatinib, crizotinib and regorafenib, to block cancer cell growth, to inhibit the mitogen-activated protein kinase (MAPK) signaling pathway and to strengthen E2F-dependent transcription inhibition. In cancer xenografts models, both TKIs and cycles of fasting slowed tumor growth, but, when combined, these interventions were significantly more effective than either type of treatment alone. In conclusion, cycles of fasting or of specifically designed fasting-mimicking diets should be evaluated in clinical studies as a means to potentiate the activity of TKIs in clinical use.

KW - Cell cycle regulation

KW - E2F transcription factors

KW - Fasting

KW - MAPK pathway

KW - Tyrosine kinase inhibitors

UR - http://www.scopus.com/inward/record.url?scp=84931329276&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84931329276&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:84931329276

VL - 6

SP - 11820

EP - 11832

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 14

ER -